Provided by Tiger Fintech (Singapore) Pte. Ltd.

Relmada Therapeutics, Inc.

1.60
-0.0500-3.03%
Post-market: 1.600.00000.00%19:53 EDT
Volume:680.37K
Turnover:1.06M
Market Cap:53.11M
PE:-0.73
High:1.68
Open:1.65
Low:1.44
Close:1.65
52wk High:3.98
52wk Low:0.2404
Shares:33.19M
Float Shares:23.27M
Volume Ratio:0.12
T/O Rate:2.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1880
EPS(LYR):-2.6515
ROE:-175.12%
ROA:-95.67%
PB:3.33
PE(LYR):-0.60

Loading ...

Company Profile

Company Name:
Relmada Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2004
Employees:
17
Office Location:
2222 Ponce de Leon Blvd.,Floor 3,Coral Gables,Florida,United States
Zip Code:
33134
Fax:
- -
Introduction:
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Directors

Name
Position
Charles J. Casamento
Chairman of the Board and Director
Sergio Traversa
Chief Executive Officer and Director
Eric Schmidt
Director
John Glasspool
Director
Paul Kelly
Director

Shareholders

Name
Position
Sergio Traversa
Chief Executive Officer and Director
Maged Shenouda
Chief Financial Officer
Charles Ence
Chief Accounting and Compliance Officer
Charles J. Casamento
Chairman of the Board and Director
Marco Pappagollo
Acting Chief Medical Officer
Paolo Manfredi
Acting Chief Scientific Officer